Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces voting results for the election of directors at its Annual Meeting of Shareholders held on June 22, 2018 in Toronto, Ontario. A...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces details of its upcoming Annual Meeting of Shareholders. Date: Friday June 22, 2018 Time: 10:00 a.m. ET Location: Blake, Cassels...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it has entered into an automatic share purchase plan (the "ASPP") with a designated broker in order to facilitate...
Commenced trading on the TSX Venture Exchange (Toronto Stock Exchange) Revenue of $13.2M in Q1 2018 vs $15.6M in Q1 2017. Clozaril generates year-over-year growth; Absorica royalties reflect...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that the TSX Venture Exchange ("TSXV") has approved the Company's Notice of Intention to Make a Normal Course Issuer Bid...